Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

CDSCO releases new export NOC system to issue certificates for one year subject to conditions: Our Bureau, New Delhi Tuesday, March 11, 2025, 08:00 Hrs [IST] In an ongoing effort ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Delhi police are tightening measures to combat crime, particularly drug smuggling by foreign nationals, following a recent ...

The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain ("CINP”) trial in Q4 2025 ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- ...

President Donald Trump’s health team has deep financial ties to the supplements industry. Now they’re poised to boost its ...

Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase ...

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...

President Donald Trump is scheduled Thursday to welcome NATO Secretary General Mark Rutte to the White House. The pair are ...

The Senate Committee on Health, Labor and Pensions voted Thursday to approve Marty Makary as commissioner of the Food and Drug Administration. He will likely be confirmed in the full Senate.

On March 3, 2025, the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “SEC”) ...